Gynecologic interventions during adjuvant therapy with anastrozole or tamoxifen: results from the ATAC trial

被引：0

作者：

Duffy, SR

Distler, W

机构：

[1] St James Univ Hosp, Leeds, W Yorkshire, England

[2] Univ Klinikum Carl Gustav Carus, Dresden, Germany

来源：

BREAST CANCER RESEARCH AND TREATMENT | 2005年 / 94卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：S103 / S103

页数：1

共 50 条

[41] Time dependent effects of adjuvant tamoxifen therapy on cerebrovascular disease: results from a randomised trial
Rosell, J.
Nordenskjold, B.
Bengtsson, N-O
Fornander, T.
Hatschek, T.
Lindman, H.
Malmstrom, P-O
Wallgren, A.
Stal, O.
Carstensen, J.
BRITISH JOURNAL OF CANCER, 2011, 104 (06) : 899 - 902
[42] Cost-effectiveness analysis of anastrozole vs tamoxifen in adjuvant therapy for early stage breast cancer in the United Kingdom: the 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen alone or in combination) trial
Mansel, R.
Locker, G.
Fallowfield, L.
Benedict, A.
Jones, D.
BRITISH JOURNAL OF CANCER, 2007, 97 (02) : 152 - 161
[43] Cost-effectiveness analysis of anastrozole vs tamoxifen in adjuvant therapy for early stage breast cancer in the United Kingdom: the 5-year completed treatment analysis of the ATAC (‘Arimidex’, Tamoxifen alone or in combination) trial
R Mansel
G Locker
L Fallowfield
Á Benedict
D Jones
British Journal of Cancer, 2007, 97 : 152 - 161
[44] The anastrozole, tamoxifen, alone or in combination (ATAC) adjuvant breast cancer trial in post-menopausal women: Regional variation in knowledge of hormone receptor status prior to randomisation into the trial. The ATAC Trialists' Group.
Howell, A
ANNALS OF ONCOLOGY, 2000, 11 : 20 - 20
[45] Anastrozole is cost-effective vs tamoxifen as initial adjuvant therapy in early breast cancer: Canadian perspectives on the ATAC completed-treatment analysis
Rocchi, A.
Verma, S.
SUPPORTIVE CARE IN CANCER, 2006, 14 (09) : 917 - 927
[46] Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer
Howell, A
Cuzick, J
Baum, M
Buzdar, A
Dowsett, M
Forbes, JF
Hoctin-Boes, G
Houghton, I
Locker, GY
Tobias, JS
LANCET, 2005, 365 (9453): : 60 - 62
[47] Anastrozole is cost-effective vs tamoxifen as initial adjuvant therapy in early breast cancer: Canadian perspectives on the ATAC completed-treatment analysis
A. Rocchi
S. Verma
Supportive Care in Cancer, 2006, 14 : 917 - 927
[48] Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole
Carlson, RW
Henderson, IC
BREAST CANCER RESEARCH AND TREATMENT, 2003, 80 : S19 - S26
[49] Sequential Hormonal Therapy for Metastatic Breast Cancer after Adjuvant Tamoxifen or Anastrozole
Robert W. Carlson
I. Craig Henderson
Breast Cancer Research and Treatment, 2003, 80 (Suppl 1) : 19 - 26
[50] Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230)
Eastell, Richard
Hannon, Rosemary A.
Cuzick, Jack
Dowsett, Mitch
Clack, Glen
Adams, Judith E.
JOURNAL OF BONE AND MINERAL RESEARCH, 2006, 21 (08) : 1215 - 1223

← 1 2 3 4 5 →